ArticleJournal of advanced research2026
Synthesis and bioactivity evaluation of isoxazoline scaffolds using heterogeneous photocatalytic (3+2) cycloaddition.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe (3+2) cycloaddition is a classic method for synthesizing bioactive isoxazoline and isoxazole heterocycles. However, its utility is hampered by a reliance on stoichiometric halogenating oxidants, bases, and multi-step protocols, generating significant waste and limiting synthetic efficiency.
objectivesThis study aims to develop an efficient alternative to the classical (3+2) cycloaddition. Our objective was to achieve the direct synthesis of isoxazolines and isoxazoles from oximes and alkenes under mild, additive-free conditions using a heterogeneous photocatalytic system.
methodsWe employed mesoporous graphitic carbon nitride (mpg-CN) as a recyclable, metal-free photocatalyst. Reactions were conducted under visible light irradiation using oxygen as a benign terminal oxidant. The scalability was demonstrated via a continuous-flow setup. Mechanistic pathways were elucidated through a combination of experimental studies and density functional theory (DFT) calculations.
resultsVarious oximes and alkenes were successfully converted into the target heterocycles in good to excellent yields. The protocol features exceptional functional group tolerance, accommodating sensitive motifs like heterocycles and Helicid analogs. Gram-scale synthesis of pharmacologically relevant cores was achieved in a continuous-flow reactor. Mechanistic investigations indicate that an energy transfer process primarily mediates the reaction cascade. Selected synthesized compounds showed promising insecticidal activity against Plutella xylostella.
conclusionWe have developed a heterogeneous photocatalytic (3+2) cycloaddition protocol. This one-step, additive-free method provides an efficient and scalable route to valuable isoxazoline and isoxazole scaffolds, with demonstrated potential for generating bioactive molecules.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.